BioNotebook: Xencor regains rights from Amgen; plus three other deals
This article was originally published in Scrip
Executive Summary
Xencor gains greater control in Amgen pact; Zogenix buys Brabant Pharma; CTI BioPharma buys worldwide rights to tosedostat; and Takeda licenses Mersana ADC.
You may also be interested in...
Xencor's Coming Share Issue To Help Fund Immuno-Oncology Pipeline
Monrovia, California-based Xencor Inc.'s latest funding exercise is a public share offering to raise some $110m after expenses to advance its immuno-oncology pipeline.
Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees
Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.
CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Need a specific report? 1000+ reports available
Buy Reports